HC Wainwright Analysts Give HTG Molecular Diagnostics (HTGM) a $6.00 Price Target

HC Wainwright set a $6.00 price target on HTG Molecular Diagnostics (NASDAQ:HTGM) in a research note issued to investors on Friday. The firm currently has a buy rating on the medical research company’s stock.

A number of other analysts have also recently commented on HTGM. ValuEngine cut shares of HTG Molecular Diagnostics from a sell rating to a strong sell rating in a research note on Tuesday, October 10th. Zacks Investment Research upgraded shares of HTG Molecular Diagnostics from a hold rating to a buy rating and set a $2.50 target price for the company in a research note on Wednesday, November 15th. One analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the stock. The stock currently has an average rating of Hold and an average target price of $4.88.

HTG Molecular Diagnostics (HTGM) traded down $0.07 during mid-day trading on Friday, reaching $3.40. 1,529,000 shares of the company were exchanged, compared to its average volume of 4,331,960. The firm has a market cap of $40.41 and a PE ratio of -1.33. HTG Molecular Diagnostics has a one year low of $1.20 and a one year high of $13.25.

A hedge fund recently raised its stake in HTG Molecular Diagnostics stock. Granahan Investment Management Inc. MA increased its stake in HTG Molecular Diagnostics Inc (NASDAQ:HTGM) by 488.3% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 416,608 shares of the medical research company’s stock after purchasing an additional 345,798 shares during the period. Granahan Investment Management Inc. MA owned 3.33% of HTG Molecular Diagnostics worth $708,000 as of its most recent filing with the Securities & Exchange Commission. 15.15% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY WARNING: This piece of content was first published by Community Financial News and is the sole property of of Community Financial News. If you are accessing this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.com-unik.info/2018/01/09/hc-wainwright-analysts-give-htg-molecular-diagnostics-htgm-a-6-00-price-target.html.

About HTG Molecular Diagnostics

HTG Molecular Diagnostics, Inc is a commercial-stage company that develops and markets a technology platform to facilitate the routine use of complex molecular profiling. The Company’s HTG Edge and HTG EdgeSeq platforms, consisting of instrumentation, consumables and software analytics, are used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development.

Receive News & Ratings for HTG Molecular Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit